Predictors of adherence and outcome in schizophrenia Richard Drake, Senior Lecturer in Adult Psychiatry, University of Manchester.

Slides:



Advertisements
Similar presentations
Mental Health Treatment
Advertisements

Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
A Pilot Study of Satisfaction and Adherence with Antipsychotic Medication Amongst Prisoners Dr Alice Mills Mr Dan Bressington Dr Richard Gray Professor.
Attachment theory in adulthood
Double Disadvantage: The impact of childhood maltreatment and community violence exposure on adolescent mental health Charlotte Cecil Molecules of Happiness:
Self-Regulation in Chronic Disease Noreen M. Clark, Ph.D. March 23, 2002.
Overall Goals of the STEP-BD Randomized Clinical Trials Pathway Answer the question “What to do next?” when acute depression doesn’t respond to monotherapy.
“The way to recovery” GAMIAN-Europe /Eastern Europe Regional Seminar “The way to Recovery: Pharmacotherapy, Psychotherapy and Social Rehabilitation from.
Managing Chronic Mental Illness in Primary Care  The “recovery” model of managing serious mental illness  Prognosis for Recovery  Tools and frameworks.
WEST EDINBURGH SUPPORT TEAM 27 th OCTOBER 2005 Malcolm Laing.
Resilience and its Relationship with the 5-Step Method Professor Richard Velleman Emeritus Professor of Mental Health Research, University of Bath, UK.
Lecture 3: Health Psychology and Physical Illnesses I (Part 2)
TWO TOPICS DEFINITION OF MENTAL ILLNESS NATURE OF SCHIZOPHRENIA.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective Naomi Breslau, Ph.D. Department of Epidemiology Michigan State.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Models of Behaviour Change Matt Vreugde
Learning & Models of Behavior Change Diane B. Wilson EdD, RD Mary S. McLellan MS,RD Medical University of South Carolina.
The Parallel Process The Parent’s Role in the Development and Growth of the Adolescent and the Family Our Experts: Tracy, Donna, & Cam Victoria Creighton,
CENTER FOR KOGNITIV TERAPI, SCT. HANS HOSPITAL
2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.
Trauma in relation to psychosis and hospital experiences in secure settings Katherine Berry, Sarah Ford, Lorna-Jellicoe Jones and Gillian Haddock University.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
Deliberate Self Harm and Risk Assessment
HEALTH PROMOTION. Rosenstock (1966) for studying and promoting the uptake of health services Originally, the model was designed to predict behavioral.
Motivational interviewing for patients with severe mental illness
Mindfulness Skills & Psychological Flexibility with distressing voices
Cherie Levy Dianne A Vella-Brodrick School of Psychology, Psychiatry and Psychological Medicine, Monash University.
Learning and Environment. Factors in the Environment Community Family School Peers.
March 2011 | TAS11-003c Taking the tablets, Do we / should we? Slides courtesy of David Marin.
Health of vulnerable children and young people in Nottinghamshire Dr Kate Allen Public Health Consultant Sally Handley Senior Public Health Manager Nottinghamshire.
 In 5 minutes write down as many drugs as you can think of!
Introduction: Medical Psychology and Border Areas
Barriers to achieve remission and recovery in schizophrenia Prof Köksal Alptekin MD Dept of Psychiatry Dokuz Eylül University School of Medicine İzmir-TURKEY.
IEPA clinical practice guidelines for ARMS Shôn Lewis University of Manchester UK.
Marijuana and Psychosis Prepared by Dr Amir Barsoum, MD, FRCPC Home on the Hill Lecture Series Sept 16, 2015.
Schizophrenia Psychological treatments psychlotron.org.uk.
LENGTH OF FIRST HOSPITALIZATION AND OTHER PREDICTORS FOR RE-HOSPITALIZATION IN PSYCHOSES Jouko Miettunen, PhD Department of Psychiatry University of Oulu,
MANAGEMENT of FIRST-EPISODE PSYCHOSIS H.Amini M.D. Roozbeh Hospital Tehran University of Medical Sciences.
Barbara Pajk, M.N. University Psychiatric Clinic Ljubljana Barcelona,
Population Health for Health Professionals. Part III Learning and Models of Behavior Change.
Dr. Abednego Musau. School violence is widely held to have become a serious problem in recent decades in many countries. It includes violence between.
Positive and Negative Affect and Health in Lung Cancer Patients Jameson K. Hirsch, Ph.D. 1,2, H. Mason 1, & Paul R. Duberstein, Ph.D. 2 Department of Psychology,
Noor Al-Modihesh Consultant Child & Adolescents Psychiatry Coping with diabetes mellitus in adolescence.
Risk and protective factors Research-based predictors of problem behaviors and positive youth outcomes— risk and protective factors.
Readings Wenar, C. & Kerig, P. (2000)“ Disorders in the depressive spectrum and child and adolescent suicide in Developmental Psychopathology (pp ).
MethodIntroductionResults Discussion Factors Affecting Psychosocial Functioning in Serious Mental Illness and Implications for Treatment Jason E. Vogler,
Understanding Cognitive Disability in Schizophrenia Cameron S. Carter MD University of California at Davis.
EIS Training Forum Wellington, New Zealand 24th November 2015
What is a Drug?. A Drug is.. O A chemical substance, natural or human made, that changes normal body functions in some way. There is no set definition.
Chapter 14 INTRODUCTION TO CLINICAL PSYCHOLOGY, THIRD CANADIAN EDITION by John Hunsley and Catherine M. Lee.
Medication for Psychosis: Myths and Truths Demian Rose, MD, PhD UCSF Assistant Professor PREP Medical Director PREP Prevention and Recovery of Early Psychosis.
LO: To be able to describe and evaluate the Cognitive Treatment for Schizophrenia.
Psychosis: Course & Prognosis NORTH WEST SCHOOL OF PSYCHIATRY MRCPSYCH COURSE SLIDES BY DR S WHEELER.
Commissioning for Schizophrenia: How big is the problem? Richard Drake, Institute of Brain, Behaviour & Mental Health.
N ON - COMPLIANCE IN MENTAL ILLNESS 1. P ARTICIPANTS Presenting author: Karishma Karim Halani Authors: Rabia Qasim Ali Salima Karani Reema Roshan Ali.
A Cognitive Behavioral Approach to Social Phobia Allison Brayton Dr. Brett Deacon University of Wyoming.
PSYCHOTIC DISORDER Mental Health First Aid By Mental Health Commission of Canada, 2010.
Psychological Therapies of Schizophrenia. Cognitive Behavioural Therapy Aims: Challenge irrational thoughts and distorted beliefs Provide an alternative.
Assessment of Suicide Risk Dr Vivien Peeler Crisis Resolution Home Treatment Consultant Psychiatrist.
Schizophrenia Emmanuel Okenyi.
Length of receiving mental health services (years)
The development of a training programme for C-BIT
Consultant Psychiatrist and Research Fellow, IoPPN.
Integrated Treatment for Co-Occurring Disorders
Bell Ringer Open your student workbook to page 2.
Integrated Treatment for Co-Occurring Disorders
ComQuol: Users Focused Outcomes
Schizophrenia • Clinical characteristics of the chosen disorder
Presentation transcript:

Predictors of adherence and outcome in schizophrenia Richard Drake, Senior Lecturer in Adult Psychiatry, University of Manchester

What I’m Going to Tell You Non-adherence predicts poor outcome Determinants of adherence and concordance –Insight relates to degree of concordance Poor insight predicts poor outcomes –it may predict poor outcome better than adherence Insight and adherence can be changed

Predictors of Outcome in Schizophrenia Demographic –Sex, age Historical –Premorbid adjustment –DUP, Course of illness –Symptoms Behavioural –EE, Substance Misuse –Adherence, Engagement

Predictors of Outcome in Schizophrenia Demographic –Sex, age Historical –Premorbid adjustment –DUP, Course of illness –Symptoms Behavioural –EE, Substance Misuse –Adherence, Engagement

Davis & Andrukaitis 1986 J Clin Psychopharmacol 16.2%57.6% DrugPlacebo

Davis & Andrukaitis 1986 J Clin Psychopharmacol

Adherence and Chronic Illness Stopping APS suddenly: 46% relapse in 6/12 if stable 56% in two years Stopping gradually: 50% over 2 years Viguera et al 1997

Robinson D et al, Arch Gen Psych, 1999

Gaebel W et al 2002 Sz Res

Wunderink L et al 2005, 2007 MESIFOS STUDY

Determinants of Poor Adherence Maybe –isolation, youth and being male –substance abuse –more side effects or their subjective experience –more frequent doses –Better or worse cognitive function Or not, for most of the above

More recent studies Internal rather than external locus of control High EE family Poor therapeutic alliance Negative attitudes Poor insight

Influence of Others Belief in Prevention Medication Affinity Vauth R et al, 2004 Psychiatry Res

Influence of Others Belief in Prevention Medication Affinity Meaningful Work Neuro- cognition Length of Illness No symptoms Age Vauth R et al, 2004 Psychiatry Res

Insight and medication attitudes Day, J., et al Arch Gen Psych

Insight and medication attitudes Day, J., et al Arch Gen Psych

The Construct of Insight Insight said to have different dimensions –E.g. recognising sx, illness, its social consequences, & need for Rx; attributing sx to illness; “hypothetical contradiction” Insight appears to have cultural, symptomatic and neuropsychological determinants

Insight and Outcome In chronic samples predicts relapse, readmission, symptoms, objective QoL, adherence, other outcomes –perhaps including violence (esp. in short term or in forensic populations). –Perhaps not including engagement? Insight during the process of relapse predicts readmission. However, these samples select for poor IS

Why does RLS predict relapse? Re-Labelling Symptoms predicts relapse –Unlike accepting NFT, awareness of illness Chance finding? Related to identifying relapse? Related to substance misuse, EE? Related to adherence?

Recent FE naturalistic studies Poor adherence in FE –definitions vary but most involve stopping >7/7 as a minimum –Many of these will stop altogether for some time –33% over any 6 months –42-59% at some point over 1-5years

All multivariate analyses of predictors of adherence have global insight as significant –Except Coldham et al, 2002 IS predicts irregular or non-adherence Disappears when adjust for PM function, age, cannabis at 1y, family support Recent FE naturalistic studies

HBM and Adherence in a Trial Perkins et al. 2006: FE trial of APS in 254 Small effect of objective SE predicted non- adherence Lack of benefit too Negative attitudes to medication did not Awareness of benefits of medication in reducing sx. & NFT both predicted good adherence

IS and Adherence in a Trial McEvoy et al. 2006: FE trial of 251 OLZ v HPL ITAQ scale predicted time to non- adherence Type of medication did not

FE cohorts and trials Global IS predicts adherence even after attitudes to medication In detail, awareness of past and future symptom reduction predicts continued adherence Negativity about medication or perceived SE not predictive; possibly objective SE Other aspects of insight inconsistent

Insight may be improved Specific IS-focussed CBT may improve it (Turkington et al, 2002, 2006; Rathod et al 2005) –This form of CBT protected against depression Focussed CBT may alter attitudes to illness and self (Gumley et al, 2005) General CBT for psychosis may not improve IS or suicidality (Tarrier et al, 2006)

Adherence may be improved Psychoeducation about medication almost never effective Multi-modal interventions appear more likely to be effective –certainly more fashionable

Insight and medication attitudes Day, J., et al Arch Gen Psych

Adherence may be improved Combine education about meds & disorder with: –Behavioural approaches (techniques and skills, reminders, reinforcement) –Work on therapeutic relationship –Use other interpersonal relationships, feelings of loyalty etc. (“affective approaches”) May be effective individually, in groups or via services (e.g. supported housing)

Summary Certain attitudes may be more predictive of future adherence and relapse than current behaviour –There maybe a very disadvantaged subgroup –Sealing over may predict disengagement

Summary Insight is associated with suicidality –If you then become depressed and hopeless because you’re ashamed and overwhelmed –It doesn’t help if you abuse substances Insight leads to adherence and improvement, which prevents the above Specific CBT might improve IS without depression Multimodal interventions improve adherence

PD SE NFM +ve correlation-ve correlation Well AIS DSH Hosp